Current diagnostic and therapeutic approaches to invasive bladder cancer

Medicinski pregled
Jasenko Dozić, Jovo Bogdanović

Abstract

Bladder cancer is the second most common urological cancer (after prostate cancer, and before kidney and testicular tumors). After setting a diagnosis for bladder cancer, transitional cell carcinoma (TCC), 25% of pts have extravesical spread of the disease, and almost 50% dies in the follow-up period and after radical surgical procedures. About 30-40% pts develop a recurrence, even after radical cystectomy is preformed, and with negative lymph nodes. T2 stage is underestimated in 40-50% of cases, whereas lymph nodes are positive in 10% of cases in T1 stage of the disease. The aim of this study was to present modern diagnostic-therapeutic procedures, which are being used in multimodal treatment of invasive bladder tumors (surgery, chemotherapy, radiotherapy), indications for their use, and treatment outcome in regard to the stage of the disease. Pathological diagnosis is a key factor for correct and on-time treatment. Pathological diagnosis is made by the biopsy of the tumor. Clinical diagnosis is made by using modern diagnostic procedures (ECHO, CT, MRI, PET scan), and tumor markers (DNA content, p-53, E-Catherine, pRb -retinoblastoma, BCL-2, PCNA, telomerase, NMP-22, BTA-test, etc.). Treatment of bladder tumors is multimodal, ...Continue Reading

References

Jul 11, 1986·JAMA : the Journal of the American Medical Association·D N MohrL J Melton
Feb 26, 1999·The Journal of Urology·H W HerrV E Reuter
Sep 24, 1999·The Urologic Clinics of North America·D G BostwickL Cheng
Mar 4, 2000·The Urologic Clinics of North America·R Lee, M J Droller
Mar 29, 2000·BJU International·C N Sternberg, F Calabrò

❮ Previous
Next ❯

Citations

May 11, 2011·Medicinski pregled·Drina JankovićPavle Glodić

❮ Previous
Next ❯

Related Concepts

Related Feeds

22q11 Deletion Syndrome

22q11.2 deletion syndrome, also known as DiGeorge syndrome, is a congenital disorder caused by a partial deletion of chromosome 22. Symptoms include heart defects, poor immune system function, a cleft palate, complications related to low levels of calcium in the blood, and delayed development. Discover the latest research on this disease here.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.